Indolent B-cell non-Hodgkin lymphoma (indolent B-cell NHL) is an umbrella term for a group of slow-growing cancers that arise from B lymphocytes, a type of white blood cell involved in immune function. These lymphomas are characterized by a typically gradual disease course, and many individuals live with the condition for years before treatment is required. The group encompasses several distinct subtypes, including follicular lymphoma, Waldenstrom macroglobulinemia, marginal zone lymphoma, lymphoplasmacytic lymphoma, indolent primary cutaneous B-cell lymphoma, and B-cell chronic lymphocytic leukemia. Precise prevalence estimates are not well established for the umbrella category. These conditions are acquired lymphomas arising from somatic changes in B cells during a person's lifetime and are not caused by inherited genetic changes. This summary reflects clinical data available as of 2026.

Symptoms of indolent B-cell NHL vary depending on the specific subtype, the extent of disease, and sites of lymph node and organ involvement. Many individuals have few or no symptoms at diagnosis and are identified incidentally through blood tests or imaging. When symptoms occur, they may include painless swelling of lymph nodes in the neck, armpits, or groin, fatigue, a feeling of fullness or discomfort in the abdomen if the spleen or abdominal lymph nodes are enlarged, night sweats, unintentional weight loss, and, in some subtypes, changes in blood counts leading to increased susceptibility to infection. Not all individuals experience all features, and severity varies considerably. Some people experience periods of stability interspersed with episodes of increased disease activity.

Indolent B-cell NHL arises from acquired changes in B lymphocytes that occur during a person's lifetime. These are not inherited conditions; they result from somatic (non-germline) alterations in immune cells. The precise triggers that initiate these cellular changes are not fully understood. Factors such as immune system dysregulation, certain infections, environmental exposures, and age-related changes in immune cell biology are thought to contribute to the development of these lymphomas in some individuals. Because these are acquired malignancies, they do not follow Mendelian inheritance patterns and do not run in families in the way that hereditary genetic conditions do.

Diagnosis of indolent B-cell NHL typically involves a combination of clinical evaluation, laboratory tests, imaging studies, and tissue biopsy. Lymph node or tissue biopsy with pathological and immunophenotypic analysis is generally required to confirm the specific subtype and guide treatment planning. Blood tests including complete blood count and protein electrophoresis may reveal abnormalities depending on the subtype. Imaging studies such as CT or PET scans are used to assess the extent of disease involvement. Bone marrow biopsy may be performed in some cases. Staging helps characterize how widely the disease has spread and informs treatment decisions. Accurate subtype classification is important because treatment approaches differ among the various entities within this umbrella.

Treatment for indolent B-cell NHL is individualized based on the specific subtype, disease stage, extent of symptoms, and patient preference. For many individuals with limited symptoms and slowly progressing disease, an approach of active surveillance (watchful waiting) may be appropriate initially. When treatment is needed, management typically involves a multidisciplinary oncology team and may include systemic therapy approaches, local or regional therapies such as radiation, and, in selected situations, other treatment modalities. Specific treatment selection depends on the subtype, patient factors, and goals of care, which may be directed at long-term disease control. Individuals are encouraged to work closely with a specialized hematology-oncology team to determine the most appropriate approach. Several additional therapies are under active investigation in clinical trials. Consulting with your healthcare provider is essential to determine the most appropriate treatment plan for your specific situation.

The prognosis for individuals with indolent B-cell NHL varies by subtype, stage at diagnosis, and individual factors. As a group, these lymphomas are generally characterized by a slow disease course, and many individuals live for many years with the condition. However, outcomes are highly variable among the different subtypes, and some individuals may experience transformation to a more aggressive form of lymphoma over time. Regular follow-up and monitoring are important. Outcomes depend on the specific subtype, response to treatment when initiated, and access to specialized oncology care. Individuals are encouraged to discuss prognosis and long-term expectations with their oncology team.

Indolent B-cell NHL is an active area of oncology research, with several clinical trials currently investigating new treatment strategies. Studies are exploring novel biologic therapies, combination regimens, cell-based approaches including CAR-T cell therapies, and radiotherapy optimization. Research is also focused on understanding biological differences among subtypes to improve treatment personalization. Individuals interested in participating in clinical trials can search ClinicalTrials.gov or discuss opportunities with their oncology team.